As such, monocytes differentiating in the tumor are a critical component of the PD1 ICB anti-tumor immune response and provide a target for rational combination therapy, including agonistic anti-CD40 antibodies, and can be designed to increase its success rate in survival benefit. The gene discussed is CD40; the disease is neoplasm.